MoneyWorks4Me

Zydus Lifesciences informs about press release

11 Dec 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated December 11, 2023 titled ‘Zydus and Daewoong Pharmaceutical announce exclusive licensing agreement for development and commercialization of Leuprolide Long-Acting Injectable in the U.S’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1109.20 -7.80 (-0.70%)
19-Aug-2026 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1894.70
Dr. Reddys Labs. 1169.75
Cipla 1419.00
Lupin 2222.00
Zydus Lifesciences 1109.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: